• What is the Best Management Strategy for Patients With NAFLD?

What is the Best Management Strategy for Patients With NAFLD?

Management of patients with non-alcoholic fatty liver disease (NAFLD) requires combined efforts of general practitioners, hepatologists, and other experts, Herbert Tilg explains in a Mentoring, Education, and Training Corner article in the August issue of Gastroenterology. NAFLD has become the most common liver disease worldwide. It ranges from simple steatosis in the absence

Read more
  • What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

Magnetic resonance elastography (MRE) is more accurate than transient elastography (TE) in identifying liver fibrosis of stage 1 or more, researchers report in the February issue of Gastroenterology, using biopsy analysis as the standard. They also show that MRI-based proton density fat fraction (MRI-PDFF) analysis is more accurate than TE-based

Read more
  • Can Vitamin D Affect Risk of Ulcerative Colitis Relapse?

Can Vitamin D Affect Risk of Ulcerative Colitis Relapse?

Serum levels of vitamin D of 35 ng/mL or less in patients with ulcerative colitis (UC) in clinical remission are associated with disease relapse, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Increasing patients’ levels of vitamin D might reduce their risk for UC relapse. Vitamin D

Read more
  • This is Your Brain on Anti-TNF Therapy

This is Your Brain on Anti-TNF Therapy

Anti-tumor necrosis factor (anti-TNF) agents rapidly reduce pain perception in brains of patients with Crohn’s disease, researchers show in the October issue of Gastroenterology. This observation could explain how clinical disease activity is often reduced long before signs of mucosal healing. Patients with Crohn’s disease treated with anti-TNF agents often report reductions in abdominal pain

Read more
  • A Quantitative Ultrasound Technology to Identify Patients with NAFLD and Quantify Steatohepatitis

A Quantitative Ultrasound Technology to Identify Patients with NAFLD and Quantify Steatohepatitis

A new quantitative ultrasound (QUS)  can accurately identify patients with non-alcoholic fatty liver disease (NAFLD) and quantify hepatic steatosis, researchers report in the July issue of Clinical Gastroenterology and Hepatology. With further validation, QUS could be an inexpensive, widely used technique to screen the general or at-risk population for NAFLD. The estimated prevalence of NAFLD

Read more